Skye Bioscience has entered into an agreement to combine with privately held fibrotic disease biotech Redx Pharma in a deal that will net $125 million in financing for the new public company, called Fibrx Therapeutics.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
Skye Bioscience has entered into an agreement to combine with privately held fibrotic disease biotech Redx Pharma in a deal that will net $125 million in financing for the new public company, called Fibrx Therapeutics.